Various TGF-β inhibitors are currently being tested in different cancers and investigated for their activity on NK cells, including Vactosertib (TEW-7197), an orally bio-available inhibitor of the TGFBRI, tested in phase I studies for advanced solid tumors (NCT02160106) or in association with the IMiD drug Pomalidomide for multiple myeloma (NCT03143985), where NK cells play a relevant role in the control of plasma malignant cells in the bone marrow. The gene discussed is TGFB1; the disease is cancer.